Dynamic SCC-Ag monitoring for predicting recurrence and metastasis in patients with cervical squamous cell carcinoma after definitive concurrent chemoradiotherapy
Frontiers in Medicine · 18.11.2026 · 13
DOI: 10.3389/fmed.2026.2002111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 18.11.2026. Verfasst von Yanan Song und 4 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To investigate the predictive value of dynamic serum squamous cell carcinoma antigen (SCC-Ag) levels and imaging characteristics for recurrence and metastasis in patients with cervical squamous cell carcinoma (CSCC) after definitive chemoradiotherapy.
Methods
This retrospective study included 215 patients with CSCC who underwent definitive concurrent chemoradiotherapy at the Second Hospital of Dalian Medical University between January 2018 and July 2025. Clinical characteristics, serial SCC-Ag levels, tumor size, and 18F-FDGPET/CT parameters were collected. Logistic regression, Cox regression, and receiver operating characteristic (ROC) curve analyses were performed to identify predictors of recurrence, metastasis, and survival outcomes.
Results
Post-external beam radiotherapy (EBRT) SCC-Ag level and residual cervical tumor size after EBRT were independent predictors of recurrence and metastasis. SCC-Ag levels at different treatment stages showed different predictive performances, with post-EBRT and end-of-treatment SCC-Ag demonstrating superior predictive ability (AUC=0.66 and 0.68, respectively). An end-of-treatment SCC-Ag cutoff value of 1.33 ng/mL effectively stratified patients with significantly different overall survival and recurrence-free survival. Larger residual tumor size after EBRT was associated with increased recurrence risk (AUC=0.61). PET/CT metabolic parameters showed potential risk stratification value but did not reach statistical significance. Dynamic analysis combining SCC-Ag and imaging findings identified patients with persistent SCC-Ag elevation before radiological recurrence, providing an early warning window.
Conclusions
Dynamic SCC-Ag monitoring, particularly post-EBRT and end-of-treatment SCC-Ag levels, combined with residual tumor size, may provide valuable prognostic information for recurrence risk stratification and survival prediction in CSCC patients after chemoradiotherapy. Integration of biomarker and imaging-based temporal analysis may facilitate individualized surveillance strategies.
Zitieren
APA
Song, Y., Wang, X., Zou, K., Zhang, F., & Zou, L. (2026). Dynamic SCC-Ag monitoring for predicting recurrence and metastasis in patients with cervical squamous cell carcinoma after definitive concurrent chemoradiotherapy. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.2002111
Vancouver
Song Y, Wang X, Zou K, Zhang F, Zou L. Dynamic SCC-Ag monitoring for predicting recurrence and metastasis in patients with cervical squamous cell carcinoma after definitive concurrent chemoradiotherapy. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.2002111
BibTeX
@article{Song2026,
author = {Song, Yanan and Wang, Xin and Zou, Kun and Zhang, Feng and Zou, Lijuan},
title = {Dynamic SCC-Ag monitoring for predicting recurrence and metastasis in patients with cervical squamous cell carcinoma after definitive concurrent chemoradiotherapy},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.2002111}
}
EUVIMED